[NEWSMP] The outlook for the Korea’s bio-health industry, which had been steadily deteriorating, has seen a sharp turnaround following the launch of the new government, drawing renewed attention.According to the “Industrial Economic Expert Survey Results (June 2025 Status and July Outlook)” publishe

[NEWSMP] Among pharmaceutical and biotech companies with a December fiscal year-end included in the Pharmaceuticals Index for the KOSPI and KOSDAQ markets, 46 companies achieved double-digit operating profit margins in the first quarter (based on separate financial statements).Notably, 14 of these c

[NEWSMP} In the first quarter of this year, Korea achieved a trade surplus in pharmaceutical products with the United States and Germany.Traditionally, the United States and Germany have been Korea’s top two trading partners in pharmaceutical products and have recorded large trade deficits.However,

[NEWMP] Last year, Listed pharmaceutical companies managed to achieve sales growth rate of 5% (excluding biotechs).However, small-sized pharmaceutical companies with annual sales below 100 billion KRW struggled, with more than half experiencing a decline in sales. Meanwhile, the growth rate of mid-s

[NEWSMP] Last year, the combined annual sales growth rate of the top five pharmaceutical companies remained at around 3%, while operating profit and net profit declined significantly. In particular, the performance varied greatly among companies, with some reporting gains and others facing losses.Ac

[NEWSMP] The combined market capitalization of the 47 constituent stocks of the KOSPI Pharmaceutical Index grew by approximately 25 trillion KRW in 2024. However, only 10 out of the 47 stocks recorded an increase in share prices during this period.According to the Korea Exchange, as of the closing p

[NEWSMP] The Bank of Korea and the Korea Institute for Industrial Economics and Trade (KIET) continue to offer diverging outlooks on the performance of the pharmaceutical industry.While KIET maintains a positive outlook, the Bank of Korea's report remains largely pessimistic. However, both reports o

[NEWSMP] Publicly traded pharmaceutical companies, which had experienced a significant slowdown in growth due to the COVID-19 endemic and medical crisis, successfully rebounded in the third quarter.Newsmp compiled third-quarter reports from listed pharmaceutical companies with fiscal year-ends in No

[NEWSMP] Last year, medium-sized enterprises in the manufacture of pharmaceuticals, medicinal chemicals and botanical products industry showed impressive performance, while small enterprises continued to struggle.According to the "2023 Financial Statement Analysis" released by the Bank of Korea on t

[NEWSMP] There is keen interest in the outlook of the pharmaceutical manufacturing industry, as recent survey results from the Bank of Korea and the Korea Institute for Industrial Economics & Trade (KIET) show divergent views.According to the Bank of Korea’s recently released September 2024 Business

[NEWSMP] As the medical supplies index rose sharply, exceeding the 16,000 mark for the first time in nearly two years, the combined market capitalization of 47 constituent stocks also surpassed 150 trillion won.In particular, 12 of the 47 constituents of the medical supplies index gained more than 1

[NEWSM] PAmid global Big Pharma continues to recover from the impact of the COVID-19 endemic, obesity treatments are creating a new landscape.According to second-quarter reports from major global Big Pharma companies compiled by Newsmp, most of them expanded their growth compared to the first quarte

[Newsmp] Huonslab, a subsidiary of Huons Global Co., Ltd., S. Korea announced the grant of process patent on the manufacturing methods of recombinant human hyaluronidase (HyDIFFUZE™), which facilitates the conversion of IV injection to SC Injection.The patent grant secures Huonslab an optimized cell

[NEWSMP] The pharmaceutical and biotech stocks, which struggled throughout the first half of the year, have been surging after entering the second half.According to the Korea Exchange, one-quarter of the top 100 stocks in terms of share price change in the KOSPI market from July 1th to the July 12th

[NEWSMP] In the first half of the year, the number of drugs (including biologics) approved by the Ministry of Food and Drug Safety decreased by nearly 20% from the same period last year.According to the Ministry of Food and Drug Safety, a total of 187 companies received approval for 627 drugs in the

[NEWSMP] In the first quarter, more than half of the top pharmaceutical companies saw an increase in merchandise sales portion. However, the average merchandise sales portion decreased slightly. (Based on separate financial statements)Newsmp compiled merchandise sales portion through quarterly repor

[NEWSMP] While the performances of global big pharma companies have been mixed, they are increasing their growth rate, emerging from the impact of COVID-19.According to the first quarter report of major global big pharma companies compiled by Newsmp, Novo Nordisk and Lilly maintained strong growth,

[NEWSMP] Despite the medical crisis in the first quarter, top pharmaceutical companies reported satisfactory financial results. However, the results were quite mixed by company.While all of the top five pharmaceutical companies reported preliminary first-quarter results, Newsmp compiled the sales an

[NEWSMP] 7 stocks up double digits in Medical Supplies index...47 constituents combined market capitalization returned to 130 trillion levelThe combined market capitalization of the 47 constituents of the Medical Supplies index has recovered to the 130 trillion won level.According to the Korea Exch

[NEWSMP] Even as global big pharma’s growth has slowed down as the COVID-19 pandemic winds down, the burden of R&D expenses for big pharma has increased significantly.Newsmp recently compiled reports from the major global big pharma companies that have released their annual results for 2023, and fou